RCG Intel

?? ???????????? ???????? ?????? American College of Rheumatology ???????? ???????????????????????? ? UCB and Biogen presented efficacy and safety results from the Phase 3 PHOENYCS GO study of dapirolizumab pegol (DZP) for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) ? Key Highlights: ? ?????????????????? ???????????? ??????????????: ?????? ?????????? ?????????????????? ???????????????????? ???????????? ?????????????? ?????? ?????? ?????????????????? ?????? + ?????? ???? ???????????????? ???? ?????????? ?????????????????? ?????? ?????????? ? ?????????????? ??????????????????: ?????? + ?????? ?????? ?????????????? ???????????????? ???????????????????? ?????????????????????? ???????????????? ???? ?????????? ????. ?????? + ?????? ?????? ???? ???? ???? ? ?????????????????? ??????????????????: ???????????????????? ?????????????????? ?????????????????? ?????????????????? ???????????????? ???????????????????????? ???? ?????? ?????? ?????????? ???? ???????????????? ???? ??????-?? ????????????????, ????????????-????, ???????????????????????????? ????????????????, ??????????, ?????? ???????????????????? ???? ???????????? ?????????? ???????????? Together, let’s navigate the development of autoimmune treatment! If you’re in Washington for ACR, don’t miss the chance to connect with?our co-founder?Drew Fussner, MBA?-?your go-to?partner?for cutting-edge CI and strategic?needs! ? Book a meeting now:?https://lnkd.in/ggcAESHs ? #PharmaCI?#ACR2024?#PharmaConsulting?#StrategyConsulting?#RCGIntel?#InsightPartner?#CompetitiveIntelligence?#StayAhead?#AutoimmuneTherapies #ImmunologyInnovation #SLE

?? ???????????????? ?????????????? ???????? ?????? American College of Rheumatology ???????? ???????????????????????? ? Cabaletta Bio presented initial positive clinical findings of the CABA-201 Phase 1/2 RESET programs for the treatment of SLE, Myositis and SSc. ? ?????? ????????????????????: ·???????Based on the early findings, CABA-201 appears to have a favorable risk-benefit profile ·???????All patients discontinued all immunosuppressants supporting potential for drug-free clinical responses ·???????In the RESET-SLE study, the first SLE patient completed steroid tapering to discontinuation and was completely off prednisone ·???????For the DM patient in RESET-Myositis study, the CDASI-A score improved from 25 to 9 at one month of follow-up ? Let’s explore the advances in autoimmune treatment together! If you’re in Washington for ACR, don’t miss the chance to connect with?our co-founder?Drew Fussner, MBA?-?your go-to?partner?for cutting-edge CI and strategic?needs! Book a meeting now:?https://lnkd.in/ggcAESHs ? #PharmaCI?#ACR2024?#PharmaConsulting?#StrategyConsulting?#RCGIntel?#InsightPartner?#CompetitiveIntelligence?#StayAhead?#AutoimmuneTherapies #ImmunologyInnovation #SLE #idiopathicinflammatorymyopathy #systemicsclerosis #SSc

? Breaking Ground in Rheumatology at #ACR24 #WashingtonDC ? UCB delivers powerful insights from its two-year clinical evaluations of BIMZELX for Psoriatic Arthritis (PsA), Non-Radiographic Axial Spondyloarthritis (nr-axSpA), and Ankylosing Spondylitis (AS). The data speaks volumes about durability and efficacy: ?? PASI100: Up to 80.6% maintained response for 2 years! ?? ASAS40: 85.7% sustained response at 2 years in AS patients. ?? Safety First: Low uveitis rates and TEAE management. With presentations spanning pivotal studies—BE OPTIMAL, BE COMPLETE, BE MOBILE, and more - UCB continues redefining possibilities in immunology. Stay tuned for actionable insights or reach out for customized analyses. Let’s explore the advances in PsA, nr-axSpA, and AS treatment together! ?? ? If you’re in Washington for ACR, don’t miss the chance to connect with?our co-founder Drew Fussner, MBA -?your go-to?partner?for cutting-edge CI and strategic?needs! Book a meeting now: https://lnkd.in/ggcAESHs #PharmaCI #ACR2024 #PsA #PsoriaticArthritis #PharmaConsulting #StrategyConsulting #RCGIntel #InsightPartner #CompetitiveIntelligence #StayAhead

?????? ???????????????????? ?????????????? ???? ?????? American College of Rheumatology (??????) ?????????????????????? ???????? ?????????? ?????? ??????????! ? RCG Intel is thrilled to connect with industry experts and explore the innovations and progress in the field of rheumatology at #ACR24. ? ????????’?? ?? ?????????????? ???? ?????? ???????? ?????????????????????????? ?????? ??????: ? ??Tremfya in Focus: Insights from a Rheumatologist, Dermatologist, Gastroenterologist ??Educational Symposium on Axial Spondyloarthritis and Psoriatic Arthritis ??Novel Therapy: Explore a new treatment for PsA, nr-asSpA, and AS ??Enlightening Oral Abstracts: Highlights from key oral abstracts on ongoing clinical studies and real-world patient data ? Let’s explore the advances in PsA treatment together! ? If you’re in Washington for ACR, don’t miss the chance to connect with?our co-founder?Drew Fussner, MBA?-?your go-to?partner?for cutting-edge CI and strategic?needs! Book a meeting now:?https://lnkd.in/ggcAESHs #PharmaCI #ACR2024 #PsA #PsoriaticArthritis #PharmaConsulting #StrategyConsulting #RCGIntel #InsightPartner #CompetitiveIntelligence #StayAhead

?? Exciting Updates from the American College of Rheumatology 2024 Convergence?? RCG Intel team will be attending ACR 2024 in Washington, D.C. and wanted to share some of the key SLE presentations expected during the conference: ?? Path to Remission in SLE: Experts explored defining a path to remission for patients with Systemic Lupus Erythematosus (SLE) ??CAR T-Cell Therapy for Autoimmune Diseases: Presentations on investigating the past, present, and future of CAR T-cell therapy for autoimmune diseases ??Clinical Profile of SAPHNELO (anifrolumab-fnia): An expert review of the TULIP pivotal trials and 4-year long-term extension study for this SLE treatment. ??Novel Biomarkers in SLE: Discussions on the role of novel biomarkers in diagnosing Systemic Lupus Erythematosus (SLE) ??Exciting Oral Abstracts: Highlights from key oral abstracts on topics like, safety and efficacy of CAR T-cell therapies, and long-term studies on combination and monotherapy treatments for SLE. Lots of promising advancements in the SLE treatment landscape! Let us know if you have any questions. If you’re in Washington for ACR, don’t miss the chance to connect with?our co-founder?Drew Fussner, MBA?-?your go-to?partner?for cutting-edge CI and strategic?needs! Book a meeting now:?https://lnkd.in/gE-uQb3D AstraZeneca, GSK, Bristol Myers Squibb, AbbVie, Cabaletta Bio, Exagen Inc., Novartis, Eisai US, Eisai Co., Ltd., UCB, Biogen ? #PharmaCI #ACR2024 #SLE #Rheumatology #Lupus #PharmaConsulting #Strategyconsulting #RCGIntel #Insightspartner #competitiveintelliegnce #Stayahead

Thank you for your service! #Gratitude #VeteransDay #thankyourforyourservice #americandream #honoringourheros #RCGIntel

??????????????? ??????????!??? We’re headed to ACR 2024 Convergence! Tired of?"Reports with?Generic?Insights?" So are we. At RCG Intel, we’ve been in your shoes—we get the high stakes and the demands, both inside and out. That’s why we deliver insights with real strategic actions, keeping you not just on track, but?ahead of the game. If you’re in Washington for ACR, don’t miss the chance to connect with?our co-founder?Drew Fussner, MBA -?your go-to?partner?for cutting-edge CI and strategic?needs! Book a meeting now:?https://lnkd.in/gE-uQb3D ? #PharmaCI #ACR2024 #Rheumatology #Psoriasis #PsoriaticArthritis #biosimilars #PharmaConsulting #Strategyconsulting #RCGIntel #Insightspartner #competitiveintelliegnce #Stayahead

Let’s boo this???! RCG Intel, your strategic partner wishes you a Happy Halloween! #HappyHalloween #HalloweenCelebration #RCGIntel #StrategicPartner

Let’s boo this???! RCG Intel, your strategic partner wishes you a Happy Halloween! #HappyHalloween #HalloweenCelebration #RCGIntel #StrategicPartner

RCG Intel Wishes you a Happy Diwali! This Diwali, may you be blessed with endless joy, health, and good fortune! #HappyDiwali #HolidayFestivities #FestivalSeason #Celebration #RCGIntel